85 MEDINAT HA-YEHUDIM STREET, HERZLIYA, L3
Proxy for the Extraordinary General Meeting of Shareholders to Be Held on August 12, 2026
Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
Receives Nasdaq Notification Regarding Minimum Bid Requirement
Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash1 of NIS 43 Million
Annual General Meeting of Shareholders Approves Proposals
Becomes Aware of Bazelet Group Restructuring Proceedings
.2
Annual and Transition Report of Foreign Private Issuers
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Amended Registration Statement for Securities of Certain Foreign Private Issuers
Certificate
Registration Statement for Securities of Certain Foreign Private Issuers
No filings found
Initial Statement of Beneficial Ownership
Schedule 13D - Ownership Report
Schedule 13G - Ownership Report
Submission Upload
Correspondence
NT 20-F
Post-Effective Amendment to Registration Statement